« Return to News | Drug Sponsors

Valeant to acquire Afexa Life Sciences

Wednesday, August 31, 2011 12:25 PM

Valeant Pharmaceuticals International has agreed to acquire fellow Canadian firm Afexa Life Sciences for $76 million in cash, a figure that comfortably tops an offer made by another company based in Canada, Paladin Labs, according to PharmaTimes.

Afexa chairman William White said the Paladin offer is "inadequate even to reflect the value of our marquee product [Cold-Fx] and gives little to no value of our growth opportunities through new products and new markets.” However the Valeant bid has been accepted unanimously by the board.

As part of the agreement, Afexa, which is based in Edmonton, has a 30 days 'go-shop' period to a find a better offer. Valeant has rights to match any bid that materializes or be paid a $3.75-million termination fee if Afexa chooses another proposal.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.